MedTrace Logo

Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)

NCT04601428 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2025-03-06

No results posted yet for this study

Summary

Intra-arterial (IA) therapy is generally used to treat HCC tumors that are too extensive to excise or treat with potentially curative local therapy. IA therapy takes advantage of the fact that the blood supply of HCC comes predominantly from the hepatic artery compared with the surrounding normal liver which is predominantly supplied by portal venous blood. The intent is to deprive the HCC of its blood supply, leading to the death of the tumor. Traditionally, various methods have been used to block the HCC blood supply, but improvements are needed. This study will investigate a new agent designed in the laboratory to block only tumor blood vessels, not blood vessels in the normal liver.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

BIOLOGICAL

IA therapy of HCC with CSR02-Fab-TF

Intra-Arterial Infusion of CSR02-Fab-TF

Sponsors & Collaborators

  • Koo Foundation Sun Yat-Sen Cancer Center

    lead OTHER

Principal Investigators

  • Paul Weiden, M.D. · KFSYSCC consultant

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-26
Primary Completion
2025-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04601428 on ClinicalTrials.gov